Federal kickback law might be used to bring down drug prices, FDA commissioner suggests
(By Ike Swetlitz for STAT) WASHINGTON — The commissioner of the Food and Drug Administration, Scott Gottlieb, on Thursday suggested
Read More
Part D/Prescription Drugs
Fentanyl and other synthetic opioids contributed to more overdose deaths in 2016 than prescription painkillers
(By Lev Facher for STAT) WASHINGTON — Synthetic opioids, particularly illicit fentanyl, contributed to more overdose deaths in the United States
Read MoreHow A Drug Company Under Pressure For High Prices Ratchets Up Political Activity
(By Jay Hancock and Elizabeth Lucas for Kaiser Health News) Business looked challenging for Novo Nordisk at the end of
Read MoreBenzodiazepines: America’s ‘Other Prescription Drug Problem’
(By John Henning Schumann for NPR) Drew was in his early 30s. His medical history included alcohol abuse, but he
Read MoreDOJ requests information from Cigna, Express Scripts as merger review continues
(By Morgan Haefner for Becker’s Hospital Review) The Department of Justice requested additional information from Cigna and Express Scripts as
Read MoreAmazon failed to disrupt the prescription drug business with Drugstore.com. Could a second try succeed?
(By Casey Ross for STAT) The headlines, spurred by Amazon’s entry into the pharmacy business, were as entertaining as they
Read MoreA national drug shortage crisis is potentially affecting the care for patients undergoing anesthesia
In a recent survey of American Society of Anesthesiologists (ASA), found more than 98 percent of respondents noted that they
Read MoreMedicare drug program covers methadone only when prescribed for pain not for addiction treatment
Older Americans with Medicare drug coverage who develop a dangerous addiction there is one treatment Medicare won’t cover: methadone. Experts
Read MoreDEA plan to stem supply of prescription drugs draws skepticism
(By Lev Facher for STAT) WASHINGTON — With pressure building on the the Drug Enforcement Administration to stem the supply
Read MoreAbbVie reaches deal that guarantees monopoly pricing for the next five years for Humira
AbbVie reached a deal with biopharmaceutical firm Samsung Bioepis that prevents Samsung from selling its cheaper copy of blockbuster drug
Read More